BankingBusiness

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

Vator Securities: Advises Amniotics on 36 MSEK Rights Issue

  • Vator Securities focuses on identifying and financing growth companies as they expand and develop into tomorrow’s market leaders
  • Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid
  • The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid
  • Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund
  • The company is pioneering the harvesting and propagation of tissue-specific neonatal quality mesenchymal stem cells (MSC)
  • Amniotics has also an, by Läkemedelsverket, approved GMP facility to produce Advanced Therapy Medicinal Products (ATMPs)
Previous article
Swift: Passes on €50 million one-time discount
Next article
Added Health: Raises Over £1M
Laura M
Laura M
Laura is a financial reporter, editor, and researcher with a particular interest in fintech innovation, capital markets, and the evolving global banking landscape.

You May Also Like

FinTech

Stablecoins Gain Traction in B2B Payments

Growing interest shows potential for stablecoins in business transactions.Highlights: Stablecoins are becoming popular for business-to-business transactions.They provide improved...
FinTech

Paysend Raises $25 Million, Strengthening Expansion Plans

This new funding round aims to boost Paysend's global reach and service offerings.Highlights: Paysend secures $25 million in...
FinTech

Lloyds Tests Quantum Computing to Strengthen Fraud Detection

The bank explores advanced tech to tackle money mule networks effectively.Highlights: Lloyds is experimenting with quantum computing for...
FinTech

9fin Secures $170 Million Raise, Valued at $1.3 Billion

The fintech platform enhances its funding to accelerate growth and innovation.Highlights: 9fin raised $170 million in a recent...